DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62. https://doi.org/10.3322/caac.21203.

Article  PubMed  Google Scholar 

Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19(5):1508–16. https://doi.org/10.1245/s10434-011-2108-2.

Article  PubMed  Google Scholar 

von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kümmel S, Paepke S, Schneeweiss A, Untch M, Zahm DM, Mehta K, Loibl S. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2013;31(29):3623–30. https://doi.org/10.1200/JCO.2012.45.0940.

Article  CAS  Google Scholar 

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804. https://doi.org/10.1200/JCO.2011.38.8595.

Article  Google Scholar 

Diaz-Botero S, Espinosa-Bravo M, Goncalves VR, Esgueva-Colmenarejo A, Peg V, Perez J, Cortes J, Rubio IT. Different prognostic implications of residual disease after neoadjuvant treatment: impact of Ki 67 and site of response. Ann Surg Oncol. 2016;23(12):3831–7. https://doi.org/10.1245/s10434-016-5339-4.

Article  PubMed  Google Scholar 

Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320–7. https://doi.org/10.1016/S0960-9776(03)00106-1.

Article  PubMed  Google Scholar 

Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–22. https://doi.org/10.1200/JCO.2007.10.6823.

Article  PubMed  Google Scholar 

Laas E, Labrosse J, Hamy AS, Benchimol G, de Croze D, Feron JG, Coussy F, Balezeau T, Guerin J, Lae M, Pierga JY, Reyal F. Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of residual cancer burden (RCB) and neo-bioscore. Br J Cancer. 2021;124(8):1421–7. https://doi.org/10.1038/s41416-020-01251-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA. The Neo-Bioscore update for staging breast cancer treated with neoadjuvant chemotherapy: incorporation of prognostic biologic factors into staging after treatment. JAMA Oncol. 2016;2(7):929–36. https://doi.org/10.1001/jamaoncol.2015.6478.

Article  PubMed  PubMed Central  Google Scholar 

Kantor O, Laws A, Pastorello RG, King C, Wong S, Dey T, Schnitt S, King TA, Mittendorf EA. Comparison of breast cancer staging systems after neoadjuvant chemotherapy. Ann Surg Oncol. 2021;28(12):7347–55. https://doi.org/10.1245/s10434-021-09951-7.

Article  PubMed  Google Scholar 

de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96(10):1504–13. https://doi.org/10.1038/sj.bjc.6603756.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174–83. https://doi.org/10.1016/S1470-2045(09)70262-1.

Article  CAS  PubMed  Google Scholar 

Dowsett M, Nielsen TO, A’Hern R, Barlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103(22):1656–64. https://doi.org/10.1093/jnci/djr393.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thurlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from breast international group trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008;26(34):5569–75. https://doi.org/10.1200/JCO.2008.17.0829.

Article  PubMed  PubMed Central  Google Scholar 

Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dotson A, Ehinger A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hugh JC, Kos Z, Laenkhon A-V, Mastropasqua MG, Moria T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF, McShane LM, Dowsett M. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology. 2019;75(2):225–35. https://doi.org/10.1111/his.13880.

Article  PubMed  Google Scholar 

Zhang W, Xu Y, Wang Y, He J, Chen R, Wan X, Shi W, Huang X, Shi X, Wang J, Zha X. Prognostic analysis of three form of Ki-67 in patients with breast cancer with non-pathological complete response before and after neoadjuvant systemic treatment. Cancer Med. 2023;12(8):9363–72. https://doi.org/10.1002/cam4.5693.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23. https://doi.org/10.1093/annonc/mdt303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Healey MA, Hirko KA, Beck AH, Collins LC, Schnitt SJ, Eliassen AH, Holmes MD, Tamimi RM, Hazra A. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses’ Health Study. Breast Cancer Res Treat. 2017;166(2):613–22. https://doi.org/10.1007/s10549-017-4421-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, Toyozumi Y, Arima N. Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. Mol Clin Oncol. 2014;2(6):1062–8. https://doi.org/10.3892/mco.2014.400.

Article  PubMed  PubMed Central  Google Scholar 

Ács B, Zámbó V, Vízkeleti L, Szasz AM, Madaras L, Szentmartoni G, Tokes T, Molnar BA, Vari-Kakas S, Kulka J, Tokes AM. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. Diagn Pathol. 2017;12(1):20. https://doi.org/10.1186/s13000-017-0608-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balmativola D, Marchiò C, Maule M, Chiusa L, Annaratone L, Maletta F, Montemurro F, Kulka J, Figueiredo P, Varga Z, Liepniece-Karele I, Cserni G, Arkoumani E, Amendoeira I, Callagy G, Reiner-Concin A, Cordoba A, Bianchi S, Decker T, Glaser D, Focke C, van Diest P, Grabau D, Lips E, Wesseling J, Arisio R, Medico E, Wells C, Sapino A. Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast Cancer Res Treat. 2014;148(3):511–23. https://doi.org/10.1007/s10549-014-3192-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer. 2010;17(4):269–75. https://doi.org/10.1007/s12282-009-0161-5.

Article  PubMed  Google Scholar 

Jones RL, Salter J, A’Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009;116(1):53–68. https://doi.org/10.1007/s10549-008-0081-7.

Article  CAS  PubMed  Google Scholar 

Resende U, Cabello C, Ramalho SOB, Zeferino LC. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response. BMC Cancer. 2019;19(1):601. https://doi.org/10.1186/s12885-019-5812-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–66. https://doi.org/10.1200/JCO.19.02309.

Article  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett MS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105–22. https://doi.org/10.1200/JCO.2018.77.8738.

Article  CAS  PubMed  Google Scholar 

Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AR, Pan H, Penault-Llorca FM, Polley M-Y, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021;113(7):808–19. https://doi.org/10.1093/jnci/djaa201.

Article  CAS  PubMed  Google Scholar 

Cortazar DP, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmenn H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. https://doi.org/10.1016/S0140-6736(13)62422-8.

Article